These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28516377)

  • 1. The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Ishii H; Shimomura I; Watada H;
    Diabetes Ther; 2017 Jun; 8(3):693-704. PubMed ID: 28516377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Shimomura I; Watada H
    Diabetes Ther; 2017 Oct; 8(5):1135-1146. PubMed ID: 28933039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Diabetes Ther; 2021 Sep; 12(9):2499-2515. PubMed ID: 34357559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H
    Diabetol Metab Syndr; 2014 Mar; 6(1):35. PubMed ID: 24607023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
    Katakami N; Mita T; Irie Y; Takahara M; Matsuoka TA; Gosho M; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2018 Feb; 17(1):24. PubMed ID: 29402270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
    Ishii H; Suzaki Y; Miyata Y; Matsui S
    Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Shimomura I; Watada H
    Int J Endocrinol; 2017; 2017():1925305. PubMed ID: 28250768
    [No Abstract]   [Full Text] [Related]  

  • 11. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
    Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Sato J; Watada H
    Diabetes Ther; 2018 Jun; 9(3):1403-1412. PubMed ID: 29744822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
    Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
    Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Shimizu M; Kojima Y; Yamamto H; Yasuda D; Sato J; Watada H
    Diabetes Ther; 2019 Feb; 10(1):119-134. PubMed ID: 30483953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus.
    Okada M; Okada M; Nishigami J; Yamaaki N; Furukawa K; Ohyama K; Shimada T; Sai Y
    J Pharm Health Care Sci; 2015; 1():26. PubMed ID: 26819737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.